Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00228449 · ClinicalTrials.gov registry record · Phase 2

Peginesatide for Anemia in Chronic Hemodialysis Patients

A Phase 2 study, sponsored by Affymax.

Completed
Registry status
Phase 2
Development phase
165
Enrollment target

NCT00228449 is a Phase 2 study that has completed, run by Affymax. The registered enrollment target is 165 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00228449, a Phase 2 study, has completed, sponsored by Affymax.

COMPLETED
Registry status
Phase 2
Development phase
165 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.

Interventions

  • DRUG peginesatide

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2005-07
Est. Completion 2007-05
Phase Phase 2

Sponsor

Affymax

6 total trials

What the Registry Record Tells You About NCT00228449

The ClinicalTrials.gov registry entry for NCT00228449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affymax, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which peginesatide is the first listed.

NCT00228449 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00228449 about?

NCT00228449 is a clinical study titled "Peginesatide for Anemia in Chronic Hemodialysis Patients". The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.

What is the current status of trial NCT00228449?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2005-07. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00228449?

The interventions under investigation include: peginesatide (DRUG).

Who is sponsoring clinical trial NCT00228449?

This trial is sponsored by Affymax, which has 6 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.